

## Naura Technology (002371 CH)

## Key beneficiary of semiconductor localization

We recently held an NDR with Naura Technology's management and we maintain our positive outlook for the Company. We expect Naura to deliver robust revenue growth on capex expansion from downstream clients and accelerated semi localization trend. In addition, we believe the Company could be one of the beneficiaries of the recently launched "Big Fund III" (US\$47.5bn) in China. Naura is currently our favourite under the semi localization theme. Reiterate BUY rating for Naura (002371 CH), with an unchanged TP at RMB405.

- Geopolitical tensions have driven major economies worldwide to pursue resilience over efficiency, leading to significant investments to strengthen domestic chip fabrication capabilities. The recently established "Big Fund III" (US\$47.5bn) in China is so far the largest phase of the series, with registered capital of RMB344bn (vs. Phase I/II: RMB139bn/RMB200bn). The phase III underscores yet another Chinese government's effort to achieve self-sufficiency in semi amid the escalating geopolitical tensions. Previous phases focused on chip fabrication, equipment, materials, etc., and we expect similar investment interests for Phase III, as well as a potential focus on AI-related areas. We expect Naura to be one of the beneficiaries.
- Looking forward, Naura will likely maintain robust growth on capex expansion from clients and accelerated semi localization trend. Key drivers of revenue could be from order wins in CCP, CVD and cleanser products. The Company disclosed that new orders signed in 2023 were RMB30bn, of which 70%+ were for semiconductor equipment and 15% were for new energy/PV. We think these orders will support 40% revenue growth in 2024.
- We reiterate our BUY rating for Naura (002371 CH), with an unchanged TP at RMB405, based on the same 39x 2024E P/E. We raise our GPM forecasts by 1.9ppt and 3.9ppt for 2024/25E, considering larger revenue contribution from more advanced equipment. This accretive impact on net profit was offset by a higher projection for R&D spending (~11% of total revenue), as the Company is expanding its product coverage. Risks: 1) intensified competition from overseas and domestic peers, and 2) escalating geopolitical tensions.

### **Earnings Summary**

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E					
,										
Revenue (RMB mn)	14,688	22,079	30,856	39,030	48,443					
YoY growth (%)	51.7	50.3	39.7	26.5	24.1					
Gross margin (%)	43.8	41.1	39.8	41.5	42.3					
Operating profit (RMB mn)	2,867.5	4,447.9	6,306.2	8,944.4	12,026.3					
YoY growth (%)	131.9	55.1	41.8	41.8	34.5					
Net profit (RMB mn)	2,352.7	3,899.1	5,527.3	7,833.0	10,526.2					
YoY growth (%)	118.4	65.7	41.8	41.7	34.4					
P/E (x)	90.8	55.0	38.9	27.5	20.4					
Source: Company data, Bloombe	Source: Company data, Bloomberg, CMBIGM estimates									

## **BUY (Maintain)**

Target Price RMB405.00 Up/Downside 32.8%

Current Price RMB304.98

China Semi

Lily YANG, Ph.D (852) 3916 3716 lilyyang@cmbi.com.hk

Kevin ZHANG (852) 3761 8727 kevinzhang@cmbi.com.hk

#### Stock Data

Mkt Cap (RMB mn)	161,926
Avg 3 mths t/o (RMB mn)	1,644.98
52w High/Low (RMB)	349.48/213.42
Total Issued Shares (mn)	531

Source: FactSet

## **Shareholding Structure**

Beijing Sevenstar Huadian	33.6%
Technology Gro	
Beijing Electronics Holding	9.4%
Source: Bloombera	

Share Performance

	Absolute	Relative
1-mth	-3.1%	-9.1%
3-mth	13.3%	1.1%
6-mth	26.4%	17.7%

Source: FactSet

### 12-mth Price Performance



Source: FactSet



# National Integrated Circuit Industry Investment Fund (The Big Fund)

The National Integrated Circuit Industry Investment Fund, known as the Big Fund, was created in 2014 with registered capital of RMB139bn. The initial phase focused on developing China's semi manufacturing capabilities with major investments directing towards leading Chinese semi foundries, such as SMIC (688951 CH) and Hua Hong Semi (1347 HK). Additionally, the fund supported other parts of the semi ecosystem, such as materials and equipment, laying the groundwork for a more self-sufficient semi industry. According to ijiwei's analysis, 67% of the fund was invested in IC manufacturing, 17% in chip design, 10% in packaging, and 6% in equipment and materials.

**Big Fund II** was launched in 2019, significantly expanding its scope and financial flexibility with registered capital of RMB200bn. This phase shifted its focus to strengthening the upstream semi supply chain, particularly in equipment and materials. Investments were aimed at companies producing essential semi equipment, such as etching machines and testing equipment. Phase II also aimed to further reduce China's reliance on foreign tech and support domestic semi solutions.

**Big Fund III** is so far the largest phase of the series with registered capital of RMB344bn. This phase underscores yet another Chinese government's effort to achieve self-sufficiency in semi amid the escalating geopolitical tensions. The investments are likely to further the previous objectives (advanced materials, manufacturing capacity and equipment, etc.), while potentially adding other critical areas in AI developments.

Figure 1: History of China's Big Fund

Fund	Date	Amount	Investments
Big Fund I	2014	RMB139bn	Major investments in SMIC (688981 CH, NR) and Yangtze Memory Technologies Corp (YMTC), Hua Hong Semi (1347 HK, NR), etc.
Big Fund II	2019	RMB200bn	Continued support for SMIC, YMTC, Hua Hong Semi, and other local semi manufacturers, such as Naura Technology (002371 CH, BUY) and AMEC 688012 CH, NR).
Big Fund III	2024	RMB344bn	

Source: Bloomberg, Reuters, CMBIGM



Figure 2: CMBIGM estimates vs. consensus

	CN	CMBI estimates			Consensus			Diff (%)		
RMB mn	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	
Revenue	30,856	39,030	48,443	30,322	39,607	48,527	2%	-1%	0%	
Gross Profit	12,281	16,203	20,503	12,829	16,781	20,695	-4%	-3%	-1%	
Net profit	5,525	7,813	10,481	5,556	7,581	9,423	-1%	3%	11%	
EPS (RMB)	10.41	14.72	19.74	10.61	14.46	18.17	-2%	2%	9%	
Gross Margin	39.8%	41.5%	42.3%	42.3%	42.4%	42.6%	-2.5 ppt	-0.9 ppt	-0.3 ppt	
Net Margin	17.9%	20.0%	21.6%	18.3%	19.1%	19.4%	-0.4 ppt	0.9 ppt	2.2 ppt	

Source: Bloomberg, CMBIGM estimates

Figure 3: Earnings revision

		New			Old			Diff (%)		
RMB mn	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	
Revenue	30,856	39,030	48,443	30,477	40,625	49,229	1%	-4%	-2%	
Gross profit	12,281	16,203	20,503	11,564	15,274	18,413	6%	6%	11%	
Net profit	5,525	7,813	10,481	5,499	7,618	9,461	0%	3%	11%	
EPS (RMB)	10.41	14.72	19.74	10.37	14.37	17.85	0%	2%	11%	
Gross margin	39.8%	41.5%	42.3%	37.9%	37.6%	37.4%	1.9 ppt	3.9 ppt	4.9 ppt	
Net margin	17.9%	20.0%	21.6%	18.0%	18.8%	19.2%	-0.1 ppt	1.3 ppt	2.4 ppt	


Source: Company data, CMBIGM estimates

Figure 4: 12M forward PE band

60 50 40 30 20 10 -10 -0 -1-yr Forward P/E — Mean — Mean+1SD — Mean-1SD

Source: Company data, CMBIGM estimates

Figure 5: 12M forward PE chart



Source: Company data, CMBIGM estimates



## **Financial Summary**

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Revenue	9,683	14,688	22,079	30,856	39,030	48,443
Cost of goods sold	(5,867)	(8,250)	(13,005)	(18,575)	(22,827)	(27,940)
Gross profit	3,817	6,438	9,075	12,281	16,203	20,503
Operating expenses	(2,580)	(3,571)	(4,627)	(5,974)	(7,259)	(8,477)
Selling expense	(84)	(135)	(167)	(203)	(217)	(221)
SG&A expense	(1,705)	(2,224)	(2,836)	(3,393)	(3,921)	(4,455)
R&D expense	(1,297)	(1,845)	(2,475)	(3,305)	(4,180)	(5,189)
Others	507	633	852	926	1,060	1,389
Operating profit	1,236	2,867	4,448	6,306	8,944	12,026
Other income	18	14	22	24	27	29
Other expense	(2)	(27)	(4)	0	0	0
Pre-tax profit	1,253	2,854	4,466	6,330	8,971	12,056
Income tax	(59)	(313)	(433)	(614)	(870)	(1,169)
After tax profit	1,193	2,541	4,033	5,717	8,102	10,887
Minority interest	116	188	134	189	269	361
Net profit	1,077	2,353	3,899	5,527	7,833	10,526
not prom	.,	_,000	0,000	0,0	.,000	.0,020
BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Current assets	22,323	31,117	38,226	50,792	55,409	77,046
Cash & equivalents	9,068	10,435	12,451	16,481	19,703	27,076
Account receivables	1,899	2,995	3,767	6,039	6,365	9,030
Inventories	8,035	13,041	16,992	22,703	22,950	32,930
Prepayment	658	1,551	1,480	1,733	1,997	2,237
Other current assets	2,663	3,096	3,535	3,836	4,394	5,772
Non-current assets	8,732	11,434	15,399	19,439	23,278	26,709
PP&E	2,423	2,484	3,352	3,758	4,327	4,977
Right-of-use assets	68	147	215	282	328	353
Deferred income tax	473	363	450	572	641	845
Intangibles	2,063	2,003	2,547	3,028	3,363	3,477
Goodwill	17	18	27	27	27	27
Other non-current assets	3,689	6,419	8,808	11,772	14,592	17,030
Total assets	31,054	42,551	53,625	70,231	78,687	103,754
	, , , , , , , , , , , , , , , , , , , ,	,	,.	., .	-,	
Current liabilities	11,268	15,770	19,083	28,404	29,192	41,869
Short-term borrowings	0	227	23	308	447	605
Account payables	3,499	5,592	6,117	9,150	8,986	13,213
Tax payable	110	130	209	238	267	352
Other current liabilities	2,096	1,841	3,418	4,212	4,343	6,086
Contract liabilities	5,046	7,198	8,317	13,572	14,116	20,250
Accrued expenses	517	782	999	923	1,035	1,364
Non-current liabilities	2,588	6,797	9,717	11,651	11,852	14,233
Long-term borrowings	0	3,740	5,835	6,820	6,467	7,208
Bond payables	0	0	0	0	0	0
Deferred income	0	2	4	4	4	4
Other non-current liabilities	2,587	3,055	3,877	4,827	5,380	7,021
Total liabilities	13,856	22,567	28,800	40,055	41,044	56,102
Shara capital	Ege	E20	E20	E24	E94	E24
Share capital	526 2,924	529 5,159	530 8 776	531 13.842	531 21 041	531 30,689
Retained earnings Other reserves	2,924 13,448	14,058	8,776 15.061	13,842 15,155	21,041 15,155	15,155
Total shareholders equity	13,448 <b>16,898</b>	19,746	15,061 <b>24,367</b>	15,155 <b>29,529</b>	15,155 <b>36,728</b>	46,375
Minority interest	301	238	<b>24,367</b> 458	<b>29,529</b> 647	<b>36,726</b> 916	
•						1,277
Total equity and liabilities	31,054	42,551	53,625	70,231	78,687	103,754



CASH FLOW	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	1,253	2,854	4,466	6,330	8,971	12,056
Depreciation & amortization	460	552	730	894	1,107	1,296
Tax paid	(59)	(313)	(433)	(614)	(870)	(1,169)
Change in working capital	(3,133)	(4,424)	(3,409)	(4,883)	(1,154)	(8,067)
Others	703	603	1,012	6,407	1,096	7,935
Net cash from operations	(777)	(728)	2,365	8,135	9,151	12,051
Investing						
Capital expenditure	(447)	(1,409)	(1,980)	(4,955)	(5,061)	(4,724)
Acquisition of subsidiaries/ investments	0	(15)	(81)	na	na	na
Net proceeds from disposal of short-term	0	0	3	na	na	na
investments		4				
Others	0	1	0	(157)	143	197
Net cash from investing	(447)	(1,423)	(2,058)	(5,112)	(4,917)	(4,527)
Financing						
Dividend paid	(114)	(241)	(388)	(620)	(810)	(1,066)
Net borrowings	(602)	3,453	1,888	1,281	(214)	898
Proceeds from share issues	8,497	157	212	95	0	0
Others	(101)	(24)	(66)	(46)	(47)	(47)
Net cash from financing	7,680	3,345	1,647	709	(1,071)	(214)
Net change in cash						
Cash at the beginning of the year	2,578	9,031	10,261	12,229	16,017	19,239
Exchange difference	(4)	37	14	56	60	63
Others	6,457	1,194	1,954	3,732	3,163	7,311
Cash at the end of the year	9,031	10,261	12,229	16,017	19,239	26,613

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.



## **Disclosures & Disclaimers**

#### **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## **CMBIGM Ratings**

: Stock with potential return of over 15% over next 12 months BUY HOLD Stock with potential return of +15% to -10% over next 12 months SELL NOT RATED : Stock with potential loss of over 10% over next 12 months

: Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

### Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

## For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

## For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

## For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.